This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AVROBIO 관리

관리 기준 확인 3/4

AVROBIO's CEO는 Erik Ostrowski, Jan2019 에 임명되었습니다 의 임기는 5.42 년입니다. 총 연간 보상은 $ 1.59M, 31.7% 로 구성됩니다. 31.7% 급여 및 68.3% 보너스(회사 주식 및 옵션 포함). 는 $ 41.58K 가치에 해당하는 회사 주식의 0.065% 직접 소유합니다. 41.58K. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 6.2 년입니다.

주요 정보

Erik Ostrowski

최고 경영자

US$1.6m

총 보상

CEO 급여 비율	31.7%
CEO 임기	5.4yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	6.2yrs

최근 관리 업데이트

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

CEO 보상 분석

Erik Ostrowski 의 보수는 AVROBIO 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$30m
Dec 31 2023	US$2m	US$504k	US$12m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$101m
Dec 31 2022	US$1m	US$460k	-US$106m
Sep 30 2022	n/a	n/a	-US$109m
Jun 30 2022	n/a	n/a	-US$119m
Mar 31 2022	n/a	n/a	-US$122m
Dec 31 2021	US$3m	US$439k	-US$119m
Sep 30 2021	n/a	n/a	-US$119m
Jun 30 2021	n/a	n/a	-US$123m
Mar 31 2021	n/a	n/a	-US$121m
Dec 31 2020	US$2m	US$424k	-US$120m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$95m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$3m	US$412k	-US$73m

보상 대 시장: Erik 의 총 보상 ($USD 1.59M )은 US 시장( $USD 683.56K ).

보상과 수익: Erik 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Erik Ostrowski (52 yo)

5.4yrs

테뉴어

US$1,590,892

보상

Mr. Erik John Ostrowski, MBA, has been Chief Financial Officer and Treasurer at AVROBIO, Inc since January 2019 and served as its Principal Accounting Officer. He serves as President and Interim Chief Exec...

리더십 팀

이름	위치	테뉴어	보상	소유권
Erik Ostrowski	President	5.4yrs	US$1.59m	0.065% $ 41.6k
Azadeh Golipour	Chief Technology Officer	2.4yrs	US$1.27m	0.084% $ 53.5k
Essra Ridha	Chief Medical Officer	2.7yrs	US$1.34m	0.035% $ 22.5k
Jeffrey Medin	Scientific Founder	no data	데이터 없음	데이터 없음
Steven Avruch	Chief Legal Officer & Secretary	5.4yrs	US$1.77m	0.049% $ 31.3k
Scott Gottesman	Vice President of Human Resource	2.4yrs	데이터 없음	데이터 없음
Kirsten Dupuis	Chief of Staff	no data	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: AVRO 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ian T. Clark	Independent Director	6.4yrs	US$63.97k	0% $ 0
Phillip Donenberg	Independent Non-Employee Director	6yrs	US$72.97k	0.0044% $ 2.8k
Bruce Booth	Independent Chairman of the Board	8.3yrs	US$98.97k	0% $ 0
Philip Vickers	Independent Director	5.4yrs	US$73.97k	0.011% $ 6.8k
Gail Farfel	Director	3.7yrs	US$61.47k	0% $ 0
Annalisa Lisa Jenkins	Independent Director	6.2yrs	US$76.97k	0% $ 0
Christopher Paige	Independent Director	8.4yrs	US$72.97k	0.56% $ 358.6k

6.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: AVRO 의 이사회는 경험(평균 재직 기간 6.2 년)으로 간주됩니다.

This company is no longer active

AVROBIO 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Chief Business Officer notifies of intention to sell stock

Co- Founder exercised options to buy US$104k worth of stock.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

New 90-day low - US$15.85

CEO 보상 분석

CEO

테뉴어

보상